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ABSTRACT 
Objectives: Enhancing the dissolution rate of raloxifene hydrochloride for the preparation of rapidly disintegrating tablets with subsequent rapid 
dissolution.  
Methods: Binary and ternary solid dispersions (SDs) with different carriers were prepared at various drug: carrier ratios including cremophor RH 
40, polyvinylpyrrolidone (PVP K30), poloxamer 407 and gelucire 44/14 as carriers and were evaluated by drug content, In-vitro dissolution studies, 
Differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR) analysis analysis. The most efficient solid dispersion 
was selected for preparation of rapidly dissolving tablets. 
Results: SDs showed enhanced dissolution rate compared to the unprocessed drug. Differential scanning calorimetry revealed that enhancement in 
drug dissolution was mainly due to a change in its crystalline structure. FTIR studies revealed no interaction between the drug and excipients. The 
dissolution pattern of the drug from the prepared tablet depended on the components of the tablets with those containing a combination of super-
disintegrants (crospovidone and croscarmellose) in the presence of citric acid as channeling agent and pH modifier being the best. 
Conclusion: The study presented a system capable of increasing the dissolution rate of raloxifene with successful incorporation in rapidly 
disintegrating tablets with subsequent fast dissolution. 
Keywords: Raloxifene hydrochloride, Binary solid dispersion, Ternary solid dispersion, Raloxifene dissolution rate, Rapidly dissolving tablets. 
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INTRODUCTION 
Raloxifene hydrochloride (RHL) is an orally active, selective 
estrogen receptor modulator [1]. It has estrogen agonist effects on 
bone and cholesterol metabolism but behaves as a complete 
estrogen antagonist on uterine and breast tissue [2]. It can reduce 
the risk of spinal fractures with high potential of reducing the risk of 
invasive breast cancer in postmenopausal women with osteoporosis 
[3]. It is being investigated for the prevention and treatment of 
osteoporosis in elderly men [4, 5]. Based on the Biopharmaceutical 
Classification System, RHL is classified as Class-II drug meaning that 
the drug is highly permeable but poorly soluble [6]. This means that 
the oral bioavailability of the drug is dissolution rate limited. In 
addition, RHL suffers from extensive presystemic metabolism which 
is dominated by glucuronidation in the intestine and liver [7]. The 
combined effect of poor dissolution and extensive first-pass 
metabolism leads to a very low bioavailability (2.6±0.4%) [8] 
Accordingly, enhancing the drug dissolution is expected to increase 
the oral bioavailability of RHL. The benefit will become even greater 
if the selected excipients and/or dissolution enhancement technique 
can inhibit the presystemic metabolism [9]. In the past, several 
techniques were performed to improve the dissolution rate and 
hence the bioavailability of RHL. These include binary solid 
dispersion system [10, 11], nanoparticle engineering [12], 
bioadhesive microspheres composed of inclusion complex [13] and 
self-nano emulsifying drug-delivery systems [14]. To the best of our 
knowledge, no reports were available in the literature on ternary 
solid dispersion system with polymers having enzyme inhibitory 
potential and henceforth we made an attempt to formulate binary 
and ternary solid dispersion of the drug with different polymers 
having enzyme inhibitory potential. This together with rapid 
dissolution can provide a greater chance for the drug to escape from 
the metabolism due to enzyme saturation and/or inhibition. In 
addition, enhanced dissolution can eliminate the variability in drug 
absorption. The present study encompasses the formulation and 
evaluation of fast disintegrating tablets with subsequent rapid 
dissolution. This was achieved via a ternary solid dispersion 
formation with several carriers having an inhibitory effect on the 
UDP-glucuronosyltransferase and other metabolizing enzymes. 
These included cremophor RH 40, polyvinyl pyrrolidone (PVP K30), 
poloxamer 407 and gelucire 44/14 [15]. 
MATERIALS AND METHODS 
Materials 
Raloxifene hydrochloride (RHL), polyvinylpyrrolidone (PVP K30) 
and Aerosil 200 were obtained as generous gift samples from 
Pharaonia Pharmaceuticals Pharo Pharma, Alexandria, Egypt. 
Poloxamer 407 and Cremophor RH 40 were purchased from Basf Co, 
Ludwigshafen, Germany. Gelucire 44/14 was obtained from 
Gattefosse Saint Priest Cedex France. Tween 80 and Citric acid were 
purchased from Adwic, El-Nasr Pharmaceutical Chemical Co., Cairo, 
Egypt. Avicel PH 102, croscarmellose sodium, crospovidone, 
magnesium stearate, and sucralose were kindly supplied as gift 
samples from Sigma pharmaceutical industries, Egypt. All chemical 
reagents of analytical grade. 
Methods 
Construction of calibration curves for raloxifene HCL  
The quantification of the drug in binary and ternary solid 
dispersions and tablets as well as aqueous samples from the 
dissolution experiments were determined by UV-spectrophotometry 
(Thermo Fisher Evolution 300, Japan). A stock solution of raloxifene 
(1000 μg/ml) was prepared by weighing 50 mg of RHL which was 
quantitatively dissolved in 50 ml of methanol. This solution was 
used to prepare serial dilutions of the drug (2-10 µg/ml). The 
highest concentration was scanned with UV-Visible 
spectrophotometry in range 200 to 600 nm using methanol as a 
blank and λmax were recorded at 286 nm. The absorbance values of 
the prepared concentrations were recorded at 286 nm and a 
calibration curve was constructed by plotting the absorbance as a 
function of drug concentration. The calibration curve was linear in 
the tested range, and the standard regression equation was Y = 
(0.0714±0.0009) X–(0.0060±0.0018). 
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Preparation of solid dispersions  
Table (1) presents the composition of the prepared formulations. 
RHL binary and ternary solid dispersions were prepared by the 
solvent evaporation method. The drug was dissolved in the solvent 
system which comprised a mixture of ethanol and acetone (70: 
30%). The required amount of carrier was added under magnetic 
stirring until complete solubility. The solvent was removed 
completely by evaporation at 55±0.5 °C. Aerosil 200 was included in 
solid dispersion containing low melting point polymers to ensure 
the formation of the flowable product.  
This was achieved by mixing aerosil powder with the solid 
dispersion just before congealing. Mixing continued until the 
formation of dry product. The resultant solid dispersion was then 
powdered and stored in an airtight container until further use. 
 
Table 1: The composition of the prepared binary and ternary solid dispersion systems 
Code 
 






Poloxamer 407 Dissolution Efficiency (%)* 
Control 1 - - - - - 44±2.1 
Binary systems 
B1 1 1 - - - - 73±4.0 
B2 1 2 - - - - 75±3.0 
B3 1 3 - - - - 74±2.9 
B4 1 - 1 1 - - 57±2.3 
B5 1 - 2 1 - - 60±1.8 
B6 1 - 3 2 - - 61±1.3 
B7 1 - - 1 1 - 54±1.7 
B8 1 - - 1 2 - 55±0.3 
B9 1 - - 2 3 - 57±2.3 
B10 1 - - - - 1 65±0.7 
B11 1 - - - - 2 65±3.4 
B12 1 - - - - 3 67±1.3 
Ternary systems 
T1 1 0.5 0.5 0.5 - - 77±4.5 
T2 1 1 1 0.5 - - 81±2.6 
T3 1 0.5 - - - 0.5 70±2.2 
T4 1 - - 0.5 0.5 0.5 76±3.4 
T5 1 - 0.5 0.5 0.5 - 57±2.5 
*n = 3, data represent mean of three observations 
 
Differential scanning calorimetry 
Thermograms of the samples (RHL, excipients, binary and ternary 
solid dispersions) were recorded using a differential scanning 
calorimeter (DSC-60, Shimadzu, Japan). Samples equivalent to 2–3 
mg of the drug were loaded into aluminum pans and the lids were 
crimped using a Shimadzu crimper. The thermal behavior of each 
sample was investigated under nitrogen at a heating rate of 10 
°C/min, covering temperature ranges of 25–300 °C. The instrument 
was calibrated with an indium standard (mp= 156.5 °C, ∆Hfus= 28.41 
J/g). Data analysis was conducted using the TA-60 WS thermal 
analysis software.  
Fourier transforms infrared spectroscopy  
FTIR spectra of RHL, pvp k30, gelucire 44/14, cremophor RH 40, 
poloxamer 407 and aerosil 200, and their binary and ternary solid 
dispersions were recorded using a Bruker Tensor 27 FTIR 
spectrometer (Bruker Optics GmbH, Ettlingen, Germany) equipped 
with DLaTGS (DeuteratedL-alanine Triglycine Sulfate) detector. 
Samples were mixed with potassium bromide (spectroscopic grade) 
and compressed into discs using hydraulic press (cap 15T), before 
scanning from 4000 to 200 cm-1. Analysis of the spectra was carried 
out using the Bruker OPUS (OPtical User Software) Data Collection 
Program. 
Determination of drug content  
Samples of the solid dispersions equivalent to 60 mg of the drug 
were dissolved in minimum quantity of methanol and volume was 
made up to 50 ml. This was suitably diluted with methanol before 
the determination of the drug content using UV spectrophotometry 
at 286 nm using the solvent as blank. 
Determination of drug dissolution 
The dissolution studies employed the USP method 2 (paddle 
method) dissolution apparatus (Copley Scientific Dis 6000, 
Nottingham, United Kingdom). Water containing 0.1% w/v Tween 
80 was used as a dissolution medium (1000 ml). This was 
maintained at 37±0.5 °C and stirred at a speed of 50 rpm. The drug 
(60 mg or equivalent) in the form of unprocessed powder, solid 
dispersion or tablet was added to the dissolution vessels while 
stirring. Samples (5 ml) were taken at appropriate time intervals (5, 
10, 20, 30, 45 and 60) and immediately replaced with fresh 
dissolution medium to maintain sink conditions. These samples 
were subjected to immediate filtration through a 0.45 μm membrane 
filters. The first 2 ml of the filtrate was discarded and the samples 
were assayed for drug content using the UV spectrophotometry at 
286 nm, after appropriate dilution with the dissolution medium. The 
cumulative amounts of the drug dissolved (expressed as % of the 
total drug added) were plotted as a function of time to produce the 
dissolution profiles. The dissolution efficiency (DE) was calculated 
from the area under the dissolution curve at time t (determined 
using the nonlinear trapezoidal rule) and expressed as a percentage 
of the area of the rectangle described by 100 % dissolution in the 
same time [16]. In addition, the amount of drug dissolved in the first 
5 min (Q5) was calculated. These parameters were used for 
comparison. 
Preparation of rapidly disintegrating tablets (RDTs) 
The ternary SD formulation showing the best release pattern was 
used to prepare the rapidly disintegrating tablets which contained 
an amount equivalent to 60 mg of the drug per tablet. The tablets 
were prepared according to the formula presented in table 2. All 
ingredients were passed through an 800 µ sieve (sieve set according 
to DIN 4188). The powdered drug or its equivalent SD was mixed 
with all excipients other than lubricant for 5 min using the bottle 
method. The obtained blend was lubricated with magnesium 
stearate for another 5 min, before compression into tablets, 
weighing 608 mg using 14 mm punch. This process employed a 
single punch tablet press machine (Royal artist. Mumbai, India) and 
the compression force were adjusted to produce tablets having a 
hardness of 4-5 kilopond. The hardness tests were performed by 
Hardness tester (Erweka Apparatus TB24, Germany) [17]. 
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RHL or an equivalent SD (T2) 210 60 210 210 60 
Avicel PH 102 300 450 300 300 450 
Croscarmellose sodium 25.5 25.5 25.5 51 25.5 
Crospovidone 25.5 25.5 25.5 ‒ 25.5 
Citric acid  ‒ ‒ 12 12 12 
Sucralose 20 20 20 20 20 
Aerosil 200 10 10 10 10 10 
Magnesium stearate 5 5 5 5 5 
Total tablet weight 596 596 608 608 608 
Disintegration time(sec)* 102±3.8 28±1.2 24±2.9 19±2.6 17±0.4  
Dissolutionefficiency (%)* 46±3.5 37±1.7 67±1.3 54±2.3 55±3.5 
*n = 3, data represent mean of three observations 
 
Evaluation of rapidly disintegrating tablets 
Uniformity of weight  
Tablets (20) were selected randomly. The weight of individual tablet 
was recorded, and the average mass and the deviation from the 
average were calculated. Not more than 2 of the individual masses 
can deviate from the average mass by more than ±5.0% and none 
can deviate by more than twice that percentage [18]. 
Tablet friability 
The friability of the tablets was measured in Friability tester (Erweka 
TA3R, Germany). A sample of whole tablets corresponding as near as 
possible to 6.5g (10 tablets) was used. The tablets are carefully deducted 
prior to testing, and the weight was recorded before being subjected to 
100 revolutions in the friabilator. Intact tablets were collected and 
subjected to a dedusting before recording the weight. If obviously 
cracked, cleaved, or broken tablets are found in the tablet sample after 
tumbling, the sample fails the test. If the results are difficult to interpret 
or if the weight loss is greater than the targeted value, the test is 
repeated twice and the mean of the 3 tests determined. A loss of less 
than 1% in weight (obtained from a single test or from the mean of 3 
tests) is considered acceptable for most products [19]. 
Uniformity of dosage units 
The individual contents of active substance of 10 dosage units taken at 
random were determined spectrophotometrically. The preparation 
complies with the test if each individual content is between 85% and 
115% of the average content. The preparation fails to comply with the 
test if more than one individual content is outside these limits or if one 
individual content is outside the limits of 75% to 125% of the average 
content. If one individual content is outside the limits of 85% to 115% 
but within the limits of 75% to 125%, the test was repeated on another 
20 dosage units taken at random. The preparation complies with the test 
if not more than one of the individual contents of 30 units is outside 85% 
to 115% of the average content and none is outside the limits of 75% to 
125% of the average content [20]. 
In vitro disintegration time 
The disintegration test was carried out using tablet disintegration 
tester (Copley Scientific, Colwick, Nottingham, United Kingdom). Six 
tablets were placed individually in each tube and basket rack is 
positioned in a 900 ml distilled water, which is maintained at 37±0.5 
°C and the time taken for the complete disintegration of the tablet 
with no palpable mass remaining in the apparatus was measured in 
seconds [21]. 
Wetting time 
This is carried out to measure the time, which is required for the 
complete wetting of tablets. A filter paper was placed in a small 
Petri dish containing 6 ml of distilled water. Allura red powder 
was placed on the surface of the tablet before placing the tablet on 
the wet filter paper. The time corresponding to the appearance of 
red color on the tablet surface was recorded and taken as the 
wetting time [22]. 
RESULTS AND DISCUSSION 
Solid state characterization of SDs 
The drug content values were in the range of 92 to 103% (w/w). 
This excludes any segregation of the drug or polymer during SD 
formation. The solid state characterization involved thermal analysis 
using the DSC, FTIR and dissolution studies. 
Differential scanning calorimetry (DSC) 
Fig. 1 and 2 present examples of DSC trace of RHL in the pure state 
and in binary and ternary solid dispersion systems. The DSC 
thermogram of RHL showed a typical single sharp endothermic peak 
at 268.41 °C with melting enthalpy 100.70 J/g (fig.1). This 
endotherm corresponds to the melting point of the drug and reflects 
its crystalline nature. The recorded data correlates well with the 
published data which revealed the melting transition in the range of 
265.9 to 271 °C for RHL [23, 24]. 
Pure pvp k30thermogram showed a broad endothermic peak with 
an onset of 50 °C and end set of 130 °C (fig. 1). This endotherm can 
be attributed to the liberation of adsorbed moisture from the 
hygroscopic polymer. The recorded thermogram is similar to that 
reported by other investigators in literature reports [25]. The DSC 
profile of pure poloxamer 407 revealed a sharp endotherm with a 
Tm of 57.28 °C. This endotherm reflects the melting transition of the 
surfactant (fig. 1). This finding agrees well with the published data 
on the same substance [26, 27]. The DSC trace of aerosil 200 (fig. 1) 
did not demonstrate any detectable endothermic or exothermic 
peaks. This thermal behavior is expected for this material taking into 
consideration the amorphous nature of aerosil. Similar explanation 
was reported after obtaining similar results and was confirmed with 
X-ray diffraction [28]. 
For pure gelucire 44/14 (fig. 1), the thermogram showed a single 
endothermic peak corresponding to its melting transition at 43.9 °C 
conforming to the specification of the material. This is in good 
agreement with the recorded data for the thermal analysis of the 
surfactant [29]. With respect to chromophore RH 40, the peak 
corresponding to melting transition which is expected to be at 20 °C 
was not recorded in the range of temperature tested. The 
thermogram revealed a broad endothermic peak at 244 °C which 
can be attributed to the decomposition of the surfactant. This finding 
correlates well with supplier specifications for this material. 
Preparation of SD of the drug with increasing concentration of pvp k30 
(fig. 1), resulted in a significant reduction in the Tm of the drug. This 
was associated with broadening of the melting transition and 
reduction in the enthalpy of the transition. The effect was intensified 
with increasing the ratio of the polymer in the SD. This effect can be 
explained on the base of amorphization of the drug after SD formation. 
Formation of amorphous structure can be attributed to the possible 
dispersion of drug molecules within the network structure of the 
hydrophilic polymer after evaporation of solvent [30]. 
Preparation of solid dispersion of RHL with gelucire 44/14 required 
the addition of aerosil 200 as a solid carrier to develop the flowable 
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product. This system showed thermal behavior which depended on 
the ratio of gelucire 44/14 (fig. 1). The Tm of the endothermic peak 
of the drug was gradually reduced with increasing the ratio of 
gelucire 44/14. The reduction in the Tm was associated with a 
reduction in the size and enthalpy of the transition. These behaviors 
can be attributed to the decrease in crystallinity of drug when 
dispersed in gelucire. A similar explanation was reported for the 
same surfactant with another drug [31]. For SDs with poloxamer 
407, the DSC traces of the SD (fig. 1) were characterized by a gradual 
decrease in the Tm of the endothermic peak of the drug with 
increasing the ratio of the surfactant. The enthalpy of the endotherm 
was marginally reduced. This finding suggests incomplete 
amorphization of the drug after solid dispersion formation with 
poloxamer 407 at the tested weight ratios. The melting transition of 
the polymer was recorded in all SDs and its Tm showed marginal 

















Fig. 2: Examples of the DSC traces of pure Raloxifene HCL (RHL), dispersion carriers and their ternary solid dispersion systems 
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Preparation of solid dispersion of RHL with cremophor RH 40 
required the addition of aerosil 200 as a solid carrier to develop the 
flowable product. The thermogram (fig. 1) showed a gradual 
reduction in the Tm and the enthalpy of the main endothermic peak 
of the drug compared to its profile in the pure state. However, the 
recorded reduction in the enthalpy did not indicate a complete 
change to the amorphous structure. 
Preparation of ternary solid dispersion (T1) of RHL with pvp k30 and 
gelucire 44/14 along with aerosil 200 at a weight ratio of 1: 0.5:0.5: 0.5, 
produced a DSC trace (fig. 2), showing a very broad endothermic peak of 
the drug. This endotherm was detected at significantly lower Tm and 
was shown to have a lower enthalpy compared to that obtained in cases 
of pure drug or the corresponding binary solid dispersions. Increasing 
proportions of the polymers abolished the endothermic peak of the drug 
as in the case of formulation T2 (1:1:1: 0.5; drug: PVP K30: Gelucire 
44/14: Aerosil 200). This effect can indicate the possible formation of 
amorphous solid in both solid dispersions.  
Preparation of ternary solid dispersion (T3) of RHL with poloxamer 
407 and pvp k30 at a weight ratio of 1: 0.5: 0.5, resulted in 
broadening of the endothermic peak of the drug with a significant 
reduction in the Tm (fig. 2). This can be attributed to the combined 
effects of PVP K30 and poloxamer 407. 
With respect to the ternary solid dispersion (T4) of RHL with 
poloxamer 407 and cremophor RH 40 in, the presence of aerosil 200 
the DSC trace (fig. 2) showed the combined effect for the two 
excipients in which the Tm was marginally reduced. 
Finally, preparation of ternary solid dispersion (T5) of the drug with 
gelucire 44/14 and cremophor RH 40 along with aerosil 200 
changed the thermal behavior of the drug compared with its 
unprocessed form (fig. 2). This change was manifest as a reduction 
in the Tm and enthalpy of the melting transition of the drug. Once 
again, this change can represent the combined effect of gelucire 
44/14 and Cremophor RH 40. 
FTIR spectroscopy  
Fig. (3 and 4) show the FTIR spectra of the drug in the pure state or 
as binary and ternary solid dispersion formulations. The spectrum of 
the pure excipients is also shown. The FTIR spectrum of the 
unprocessed drug revealed the characteristic absorption bands of 
the drug. These include that corresponds to the phenolic OH group 
which was shown at 3144 cm-1. The bands between 2800 and 3100 
cm-1 can be assigned for the stretching of aliphatic and aromatic C–H 
bonds. The peak at 1642 cm-1 can be attributed to the carbonyl group 
which shifted to right due to the conjugation. Bands between 1470 and 
1597 cm-1 can be due to the stretching vibrations of aromatic C=C. The 
band at 1466 cm-1 is due to S-benzothiofuron. The C–N stretching was 
observed as a peak at 1357 cm-1. The phenolic C–O stretching vibration 
appeared at 1233 cm-1 due to the conjugation of oxygen with the ring 
which shifts the compound to higher energy. The ether C–O–C stretching 
produced two bands, one at 1042 cm-1 for symmetric stretching and the 
other at 1207 cm-1 asymmetric stretching. Ketone C–(CO)–C stretching 
vibration appeared at 1170 cm-1. The strong band at 835 cm-1 can be 
attributed to the aromatic =C–H out of plane bending vibrations. The 
band at 807 cm-1 can be due to thiophene C–H. Two small peaks were 
recorded in 1914 and 1890 cm-1 indicating para-di-substitution on the 
aromatic ring. The recorded spectrum agrees well with that reported by 
other investigators for the same drug [32]. 
The FTIR spectrum of pure pvp k30 (fig. 3) revealed the characteristic 
peak of the carbonyl group which was recorded at 1662 cm-1. The 
hygroscopic nature of the polymer was indicated by the presence of a 
peak for the OH-stretching which was noticed at 3447 cm-1. This peak 
can be attributed to the presence of moisture and confirms the 
recorded broad endothermic in the DSC experiments. The band at 
2956 cm-1 can be due to C–H stretching [33]. 
The FTIR spectrum of the binary SD of the drug with pvp k30 (fig. 3) 
reflected overlapping of the characteristic absorption bands of the 
hydroxyl and carbonyl groups of drug and the polymer. This hindered 
the detailed investigation of the possible interaction between the drug 
and PVP. 
FTIR spectra of gelucire 44/14 (fig. 3) showed the characteristic 
peaks at 2922 and 2879 cm-1 which are related to the C–H stretch. 
The absorption band corresponding to the C=O stretching was 
noticed at 1736 cm-1. The C–H bending vibration was recorded at 
1467 cm-1 and the C–O stretching was noticed at 1355, 1280, and 
1114 cm-1. The presence of moisture was indicated by a broad band 
at 3459 cm-1. This is correlated well with the published spectrum for 
the surfactant [34]. The FTIR spectrum of aerosil 200 (fig. 3) showed 
a broad absorption band in the range of 3600–3200 cm-1. This can be 
due to the OH–stretching. This OH group results from intermolecular 
hydrogen bonding between the adsorbed moisture and the silica 
oxygen. In addition, a broad absorption band was noticed at 1115 
cm-1 and can be assigned for the strong Si–O linkage of aerosil. 







Fig. 3: FTIR spectra of Raloxifene HCL and its binary solid dispersion (SD) systems 
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The FTIR spectrum of the SD of the drug with gelucire 44/14 in the 
presence of aerosil 200 revealed the characteristic peaks of the drug 
with those corresponding to the phenolic OH and carbonyl groups 
being recorded in a similar position compared with the unprocessed 
drug (fig. 3). This eliminates any interaction between the drug and 
the gelucire. 
The FTIR spectrum of poloxamer 407 (fig.3), showed a broad band 
at ~3453 cm-1 corresponding to the O–H group with a strong 
absorption band being noticed at 2886 cm-1 due to aliphatic C–H 
stretching. The absorption band of C–O stretching was seen at 1113 
cm-1. This spectrum correlates well with the published spectrum for 
the same surfactant [36]. The recorded spectra for the binary SD of 
the drug with poloxamer 407 showed evidence for the characteristic 
band of the drug (phenolic OH and carbonyl groups; fig. 3). Overall, 
the recorded spectrum indicated no interaction between the drug 
and the polymer. The spectrum of pure cremophor RH 40 (fig. 3), 
showed the absorption band of the OH group which was seen as a 
broadband at ~ 3504 cm-1. The aliphatic CH bond was expressed as 
bi-forked band with two apices at 2861 and 2925 cm-1. The peak 
carbonyl group of the ester was found at 1734 cm-1. The ether C–O–C 
stretching was manifested as a strong broad band at 1113 cm-1. This 
spectrum is similar to that published spectrum for the same 
surfactant [37].  The FTIR spectrum of the SD of the drug with 
cremophor RH 40 in the presence of aerosil 200 revealed the specific 
peaks of the drug which were recorded in the same positions as in the 
case of unprocessed drug (fig. 3). The results were consistent with the 
data generated from DSC and confirmed the absence of any interaction 
between the drug and cremophor RH 40 in the presence of aerosil 200.  
The FTIR for the ternary solid dispersion of RHL/pvp k30/gelucire 
44/14 in the presence of aerosil 200 (T1) showed the characteristic 
bands of the drug at 3144 cm-1 (phenolic–OH) and 1600 cm-1 
(carbonyl group). Increasing the concentration of polymers in the 
ternary solid dispersion system (T2) resulted in overlapping of the 
absorption band corresponding to the phenolic OH of the drug with 
the hydroxyl group originating from the hygroscopic nature of PVP 
(fig. 4). Overall, the recorded spectrum indicated no interaction 
between the drug and the carriers.  
The FTIR for the ternary solid dispersion of RHL/pvp k30/poloxamer 
407 (T3) showed the characteristic bands of the drug at 3144 cm-1 
(phenolic–OH) slightly shifted to the left at 3207 cm-1. Also, the band 
corresponding to the carbonyl group of the drug overlapped with that 
of the carbonyl group of the PVP K30 (fig. 4). Overall, the recorded 
spectrum indicated no interaction between the drug and the carriers.  
The FTIR for the ternary solid dispersion of RHL/chromophore RH 
40/poloxamer 407 in the presence of aerosil 200 (T4) showed the 
characteristic bands of the drug at slightly different positions 
compared with the pure drug (fig. 4). So phenolic–OH and the 
carbonyl group were shown at 3207 and 1650 cm-1, respectively.  
The FTIR for the ternary solid dispersion of RHL/cremophor, RH 
40/gelucire 44/14 in presence of aerosil 200 (T5), showed a slight 
shift in the characteristic absorption bands of the drug (fig.4). The 
phenolic OH was shown at 3206 cm-1 and the carbonyl group was 
noticed at 1651 cm-1. 
In vitro dissolution study 
The dissolution pattern of raloxifene was monitored from the pure 
unprocessed state and its binary and ternary solid dispersion 
systems with different polymers. Recorded dissolution profiles are 
shown in fig. 5 and 6. These profiles were used to calculate the 
dissolution efficiency values which are shown in table1. The 
dissolution profile of unprocessed drug reveals poor dissolution. 
This is indicated by the amount of drug dissolved with time as only 
23±1.1% of the drug was dissolved in the first 5 min with a 
maximum of 60±2.6% of drug being liberated after 60 min. The 
overall dissolution efficiency during the course of study was only 
44±2.9 %. The recorded data agree well with that reported by other 












Fig. 4: FTIR spectra of Raloxifene HCL and its ternary solid dispersion (SD) systems. 
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In vitro dissolution study 
Preparation of SD of the drug with pvp k 30 resulted in a significant 
increase in the dissolution rate. This effect was evident even upon 
using the polymer at a 1:1 weight ratio with the drug. This system was 
able to increase significantly the amount drug released in the first 5 
min to reach 72±4.6% (P<0.01, compared to the unprocessed drug). 
The overall dissolution efficiency was also increased significantly to 
reach 73±4.0% (fig. 5, table: 1). Further increase in the concentration 
of the polymer did not result in significant change in the dissolution 
pattern of the drug compared with the SD system containing a 1:1 
weight ratio of the drug to the polymer. The recorded increase in the 
dissolution rate of the drug after solid dispersion formation can be 
attributed to the amorphization of the drug with the recorded results 
suggesting that most of the drug was changed to the amorphous 
structure at a 1:1 ratio with pvp k30. Solid dispersion formation with 
PVP was previously shown to enhance the dissolution rate of the drug 
with the enhancement being attributed to changing the drug crystal to 
the amorphous structure [39].  
Preparation of solid dispersion of the drug with gelucire 44/14 resulted 
in the formation of paste-like product which was adsorbed on aerosil 
200 to form free-flowing system. This system led to a significant increase 
in the dissolution rate compared with the unprocessed drug. The 
amount of drug liberated in the first 5 min was increased to reach 40, 41 
and 42%, from SD containing the drug with gelucire at weight ratios of 
1:1,1:2 and 1:3, respectively (fig. 5). Dissolution efficiency exceeded 
61±1.3% in the case of SD containing the drug with the polymer at 1:3 
weight ratio. Gelucire44/14 induced enhancement in dissolution rate 
after solid dispersion formation can be attributed to partial conversion 
of the crystalline drug to amorphous form with contribution from the 
wetting effect of gelucire which can be impacted by a reduction in 
interfacial tension between the drug and dissolution medium. The self-
emulsifying property of gelucire which keeps the drug in the solubilized 
state after emulsification was also considered in the literature [40]. It is 
important to note that the efficacy of gelucire was lower than that 
obtained in the case of pvp k30 SD. 
Preparation of the binary system of the drug with cremophor RH 40 
resulted in the formation of paste-like product which was adsorbed 
on aerosil 200 to form free-flowing system. This system resulted in 
the better dissolution of the drug compared to the unprocessed 
powder (fig. 5) with effect starting to be significant at a 1:1 weight 
ratio of the drug to the polymer. At this weight ratio the system 
liberated 43±2.3% of the drug in the first 5 min. The amount of 
drug dissolved at this time was significantly higher than that 
obtained from the unprocessed drug (P= 0.01). The overall 
dissolution efficacy was 5±1.7%. The recorded enhancement in the 
dissolution rate can be due to self-emulsifying properties of 
cremphor RH 40 with a reduction in the interfacial tension 
between the hydrophobic drug and dissolution medium resulting 
in enhancing the wettability of drug particles [41]. Minor 
contribution from partial change in the crystalline structure is 
possible as indicated from the DSC studies. It is important to note 
that incorporation of chromophore at higher concentration 
resulted in a marginal increase in the dissolution rate of the drug 
compared with the system containing 1:1 (drug to chromophore). 
This indicates that a 1:1 ratio was enough to produce the required 
wetting effect. 
Preparation of SD of the drug with poloxamer 407 resulted in a 
significant enhancement in the dissolution rate of the drug 
compared with the unprocessed powder (P<0.01). This was 
indicated in the case of SD containing the drug with poloxamer at 1:1 
weight ratio which liberate of 59±2.3% of the drug in the first 5 min. 
The overall dissolution efficiency was 65±0.7% (fig. 5, table: 1). 
Increasing the concentration of poloxamer 407 in the SD from 1:1 
(drug to surfactant) to 1:2 and 1:3 increased the amount dissolved in 
the first 5 min to reach 62±5.0% and 64±1.6%, respectively. This 
enhanced dissolution rate can be related to wetting effect, micellar 
solubilization with a contribution from decreased crystallinity. 
Similar explanation was reported for the same surfactant after 
enhancing the dissolution rate of other lipophilic drugs [42]. It is 
important to note that the recorded increase in the dissolution rate 
from SD containing a high concentration of poloxamer compared 
with that obtained from a 1:1 ratio did not satisfy the expectations. 
This can be attributed to a possible increase in viscosity of the 
diffusion layer at the higher concentration of poloxamer with 
subsequent reduction in the diffusion coefficient of the drug in the 
bulk. A similar explanation was reported for SD containing a high 
concentration of the same surfactant [43]. Recrystallization of the 
drug as poloxamer 407 may be less able to maintain the high 
concentration of drug in the supersaturated state can provide 





Fig. 5: The dissolution profiles of Raloxifene HCL from pure powder or from binary solid dispersions (Error bars were omitted for clarity, 
formulation details are presented in table: 1) 
El Maghraby et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 127-136 
 
134 
To maximize the possibility of dissolution enhancement ternary 
solid dispersions were prepared using the drug with two excipients. 
Formulation of a ternary system of the drug with pvp k30and 
gelucire 44/14 resulted in a system with a low melting point and 
required the addition of aerosil as a carrier. This ternary system 
provided a faster dissolution rate compared to both the unprocessed 
drug and the corresponding binary system. The ternary system 
containing the drug with pvp k30 and gelucire 44/14 at 1:1:1 weight 
ratio liberated 76±1.0% of the drug in the first 5 min with the 
overall dissolution efficiency approaching 81±2.6% (fig. 6 and table: 
1). The same ternary system was shown to be efficient for enhanced 
dissolution of other drugs [45]. 
The ternary solid dispersion of the drug with pvp k30and poloxamer 
407 (1:0.5:0.5) resulted in better dissolution of the drug compared 
to the unprocessed powder with effect starting to be significant 
(P<0.01) in the first 5 min (72±3.1%) revealing the better wetting 
ability of the surfactant-based polymer attributed to micellar 
solubilization of raloxifene and the better solubilizing effect of the 
hydrophilic carrier (fig. 6). The dissolution profile revealed a gradual 
decline in the release pattern after 45 min. This can be ascribed to 
possible recrystallization of the drug due to supersaturation. It is 
important to note that this effect was absent from other systems 
containing either pvp k30 or poloxamer 407. Absence of such 
phenomenon can be explained on the bases that the binary systems 
contained a higher concentration of pvp k30 which was enough to 
provide the antinucleant effect. The same reason can explain the 
absence of recrystallization process in case of a binary system 
containing poloxamer which influence the viscosity of the medium. 
In addition the recorded dissolution rate was lower in the case of 
binary poloxamer system reducing the possibility of 
supersaturation. Similar effect behavior was recorded with other 
lipophilic drugs with the process being explained similarly [46, 47]. 
In case of the ternary SD (T4) of the drug with cremophor RH 40 and 
poloxamer407, the product required incorporation of aerosil as a 
carrier to produce a free flowing system. This system was able to 
liberate significantly higher amounts of the drug compared to the 
unprocessed drug with the amount dissolved in the first five min 
reaching 67±2.1%. Overall dissolution efficiency was 76±3.4%. This 
enhancement in the dissolution rate of the drug can be explained on 
the bases of increased wettability and micelle solubilization as both 
carriers being surfactants decrease the interfacial tension between 
the drug and the dissolution solution. 
As for the previous ternary system, the solid dispersion of the drug 
with cremophor and Gelucire required addition of aerosil 200 as a 
carrier to produce a free flowing system. This system failed to 
provide rapid dissolution compared with unprocessed powder of 
raloxifene Hcl. The amount dissolved in the first 5 min was 29±3.4%. 
However, the overall dissolution efficiency was increased 
significantly compared with the unprocessed drug to reach 55±4.8% 
(fig. 6). The overall enhancement in the dissolution pattern can be 
explained by the self-emulsification property of gelucire 44/14 and 
cremophor RH 40. The release values of this ternary system were 
similar to the binary SD (B4 & B7), increasing the dissolution by 
approximately the same degree. 
It is clear from the results that the enhanced dissolution is mainly 
dependent on the type of polymer in the solid dispersion rather than 
the concentration of polymer. The rank order of dissolution 
enhancement was pvp k30>poloxamer 407>gelucire 
44/14>cremophor RH 40 for the binary systems. For ternary 
systems the order was (pvp k30&gelucire 44/14)>(pvp k30 & 
poloxamer 407)>(cremophor RH 40&poloxamer 407)>(cremophor 
RH 40 & gelucire 44/14). These results were in agreement with the 
recent studies which explained that the dissolution profile can be 
improved by preparation of SD including amorphous carrier like pvp 
k30 along with carrier has surface activity or self-emulsifying 








Fig. 6: The dissolution profiles of Raloxifene HCL from pure powder or from ternary solid dispersions (Error bars were omitted for clarity, 
formulation details are presented in table: 1). 
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The low solubility and slow dissolution of drugs is primary due to 
their hydrophobic nature which results in poor wetting of the drug 
particle with the dissolution medium. Solid dispersion formation is 
one of the effective strategies which can eliminate poor wettability 
making the first step in drug dissolution an easy process [49]. The 
benefit is even greater as this technique depends on hydrophilic 
carriers which can prevent the aggregation of fine particles exposing 
a higher surface area of drug to the dissolution medium. In addition, 
the presence of surface-active agent or/and self-emulsifying carriers 
in the solid dispersion can enhance dissolution via reduction in the 
interfacial tension preventing the formation of any water insoluble 
surface layers [50]. Finally SD formulation can create higher energy 
metastable forms of the drug which is rapidly dissolving. These 
aspects can explain the recorded dissolution enhancement of 
raloxifene hydrochloride after solid dispersion formation with 
various carriers [51]. 
Characterization of rapidly disintegrating tablets 
The prepared tablets were found to be of uniform weight because 
the maximum deviation of tablet weight was 1.32% which complies 
with the acceptance limit (±5%). This reflects good flow ability of 
the formulation. Recorded friability values were in the range of 0.28 
to 0.99%. This is acceptable based on the acceptance criteria of the 
BP. The drug content of the prepared tablets was in the range of 90 
to 101%. The tablets exhibited very short wetting time values which 
ranged from 17 to 38 s. This indicates the porosity of the tablets. 
Rapid wetting was reflected by the very rapid disintegration with 
disintegration time being less than 30 sfor all formulation except F1 
which disintegrated after 102 s. These results are expected for tablet 
formulations employing super-disintegrants like crospovidone and 
croscarmellose. Similar results have been reported for rapidly 
disintegrating tablets utilizing the same excipients [52]. 
The dissolution rate of the drug from tablets after disintegration has 
been used to determine whether the drug particles subjected to 
crushing or bonding during compression [53]. Amorphous 
raloxifene SD (T2) when subjected to the compression force a 
drastic drop in the dissolution rate of raloxifene SD from all tablet 
formulations was recorded (fig. 7). Indicating that the dissolution 
rate of raloxifene SD was influenced by the compression pressure. 
This is clear from the results of the dissolution rate of tablets which 
showed lower dissolution efficiency compared with the 
corresponding solid dispersion formulation (table: 1 and 2). 
However, the recorded dissolution pattern of raloxifene tablets 
containing the solid dispersion was better than the corresponding 
control tablet containing the unprocessed drug powder (table: 2). 
The dissolution rate of the tablets depended on the excipients with 
the addition of citric acid to the tablet ingredients enhancing the 
dissolution rate of the drug from the tablet formulation (table: 2). 
 
 
Fig. 7: Dissolution profiles of rapidly dissolving tablets. (Error 
bars were omitted for clarity. The details of tablet formulations 
are presented in table: 2) 
 
The overall results of tablet dissolution indicate the superiority of 
using a combination of super-disintegrants (croscarmellose sodium 
and crospovidone) in the ratio of 1:1 along with citric acid as the 
channel forming agent in the formulation of orally disintegrating 
tablets of RHL. In addition to the channeling effect of citric acid, it 
can modify the pH of the diffusion layer around the drug particle 
with subsequent increase in the solubility of the drug in the diffusion 
layer. This can increase the dissolution rate of the drug from the 
tablet and will explain the recorded better dissolution pattern of 
control tablets containing citric acid compared with the free citric 
acid corresponding tablets. 
CONCLUSION 
Solid dispersion technique was able to enhance the dissolution rate 
of RHL with dissolution efficiency being dependent on the type of 
the polymer rather than the concentration of polymer in the SD. 
Enhanced dissolution was mainly due to a physical change in the 
drug crystal rather than solubilizing effect of the tested polymers. 
SDs containing pvp k30 and gelucire 44/14 in presence of aerosil 
200 was selected for preparation of rapidly disintegrating tablets 
with subsequent rapid dissolution. Proper selection of tablet 
excipient was essential in preparation of rapidly disintegrating 
tablets with combination of super disintegrants being better 
especially in the presence of citric acid as a channeling agent and as 
a pH modifier. 
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